innovation Mexico is one of GSK’s growth engines in Latin America. The VP and general manager for Mexico discusses how the country is increasingly playing a strategic role for the company to get new healthcare products faster to the market by leveraging local R&D. Besides Asia Pacific and Japan,…
CNS Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research. What have been some of the biggest successes in the last three to four years for this affiliate? The greatest…
traditional medicine Dr. Hassan, founder and CEO of Healwell and House of Healin, brings research and entrepreneurship together with the aim of turning Malaysian traditions into scientific innovation. Could you share with us your entrepreneurial story and how this brought you to start Healwell? In 1989, I noticed an ancient trend…
Bayer Bayer Malaysia’s managing director, Thomas Steffen, discusses the key differences and opportunities offered by the Malaysian market and calls for more information to help the promotion of oral contraception in order to strengthen women’s role in society. As you are managing the pharmaceutical business in both Malaysia and Singapore, how…
consulting The managing partner of one of the “big four” consultancies speaks out about market entry strategies for Algeria and how Deloitte itself went about servicing the local pharmaceuticals industry among other thriving economic sectors. As a member of the “Big Four” professional services firms, what sort of offering does Deloitte…
strategy Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and highlights the affiliate’s emphasis on its clinical research and its impact on Argentina’s healthcare environment. What have been some…
clinical trials The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical research hub for the region as well as how the company is going digital. In the past ten…
pain management Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year. Mundipharma has recently entered a booming Malaysian pharmaceutical sector. What are your first impressions of the Malaysian market? Malaysia’s pharmaceutical sector…
CEO Talk In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with his company. He also offers advice to the next generation of Taiwanese pharmaceutical companies. To read the first part of…
BIOQuébec Mr. Lebrun discusses the role that BIOQuébec plays in the industry, its aims in representing several sectors and their plans for the coming years. Could you introduce BIOQuébec and its main priorities to our readers? BIOQuébec is a voluntary trade association representing Québec-based life sciences organizations. Its membership includes biotechnology…
Medicines Country Manager of Norpharma, Denmark, discusses how the company has been able to remain a market competitor while maintaining satisfactory payer prices. Since Norpharma’s founding in 1192, what are some of its key areas and products? We work in a number of strategic areas; pain management is where our heritage…
Financial Management YFY Biotech Management Company has not always been involved in the biotech sector. How has it evolved over the years? Yuen Foong Yu Group originally began as a paper mill company, which grew alongside Taiwan as the country moved from agriculture to industry. In moving away from its traditional business…
See our Cookie Privacy Policy Here